Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis

Baharak Moshiree, Renee McDonald, Wei Hou, Phillip P. Toskes

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Current pharmacologic treatments for gastroparesis have been disappointing due to the limited options available. Erythromycin ethylsuccinate is a potent prokinetic agent that stimulates gastric emptying. Recently, erythromycin has been linked to the occurrences of sudden cardiac death due to QT prolongation. Azithromycin is similar to erythromycin in structure but does not have significant drug-drug interactions as seen with erythromycin. Purpose: This study aims to determine whether azithromycin stimulates antral activity in patients with chronic gastrointestinal pain and refractory gastroparesis. Methods: Small bowel manometric data on 30 patients undergoing clinical evaluation for chronic digestive problems or documented refractory gastroparesis were reviewed. Antral activity was measured after infusion of erythromycin 250 mg intravenous and azithromycin (500 or 250 mg intravenous) given at different intervals during the small bowel manometry. The parameters measured included the total duration of effect, mean amplitude of antral contractions, duration of the highest antral contraction phase, number of cycles per minute, and the motility index. Results: Comparison of erythromycin and azithromycin at similar doses showed a similar positive effect on antral activity. However, comparison of erythromycin and azithromycin at the higher dose of 500 mg showed that the mean amplitude, duration of antral activity, and motility index were significantly increased with azithromycin (P < 0.05). Conclusions: Azithromycin stimulates antral activity similar to erythromycin and moreover has a longer duration of effect. However, unlike erythromycin, azithromycin does not have significant drug-drug interactions and may be a potential new medication for the treatment of gastroparesis and gastrointestinal dysmotility.

Original languageEnglish
Pages (from-to)675-683
Number of pages9
JournalDigestive Diseases and Sciences
Volume55
Issue number3
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Gastroparesis
Azithromycin
Erythromycin
Pressure
Pain
Drug Interactions
Erythromycin Ethylsuccinate
Gastric Emptying
Sudden Cardiac Death
Manometry
Antral
Chronic Pain
Pharmaceutical Preparations

Keywords

  • Antroduodenal manometry
  • Azithromycin
  • Erythromycin
  • Functional gastrointestinal pain
  • Gastrointestinal dysmotility
  • Gastroparesis

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. / Moshiree, Baharak; McDonald, Renee; Hou, Wei; Toskes, Phillip P.

In: Digestive Diseases and Sciences, Vol. 55, No. 3, 01.03.2010, p. 675-683.

Research output: Contribution to journalArticle

@article{acaf1bf16866440e9d01800a4df0d496,
title = "Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis",
abstract = "Background: Current pharmacologic treatments for gastroparesis have been disappointing due to the limited options available. Erythromycin ethylsuccinate is a potent prokinetic agent that stimulates gastric emptying. Recently, erythromycin has been linked to the occurrences of sudden cardiac death due to QT prolongation. Azithromycin is similar to erythromycin in structure but does not have significant drug-drug interactions as seen with erythromycin. Purpose: This study aims to determine whether azithromycin stimulates antral activity in patients with chronic gastrointestinal pain and refractory gastroparesis. Methods: Small bowel manometric data on 30 patients undergoing clinical evaluation for chronic digestive problems or documented refractory gastroparesis were reviewed. Antral activity was measured after infusion of erythromycin 250 mg intravenous and azithromycin (500 or 250 mg intravenous) given at different intervals during the small bowel manometry. The parameters measured included the total duration of effect, mean amplitude of antral contractions, duration of the highest antral contraction phase, number of cycles per minute, and the motility index. Results: Comparison of erythromycin and azithromycin at similar doses showed a similar positive effect on antral activity. However, comparison of erythromycin and azithromycin at the higher dose of 500 mg showed that the mean amplitude, duration of antral activity, and motility index were significantly increased with azithromycin (P < 0.05). Conclusions: Azithromycin stimulates antral activity similar to erythromycin and moreover has a longer duration of effect. However, unlike erythromycin, azithromycin does not have significant drug-drug interactions and may be a potential new medication for the treatment of gastroparesis and gastrointestinal dysmotility.",
keywords = "Antroduodenal manometry, Azithromycin, Erythromycin, Functional gastrointestinal pain, Gastrointestinal dysmotility, Gastroparesis",
author = "Baharak Moshiree and Renee McDonald and Wei Hou and Toskes, {Phillip P.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1007/s10620-009-1038-3",
language = "English",
volume = "55",
pages = "675--683",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "3",

}

TY - JOUR

T1 - Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis

AU - Moshiree, Baharak

AU - McDonald, Renee

AU - Hou, Wei

AU - Toskes, Phillip P.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Background: Current pharmacologic treatments for gastroparesis have been disappointing due to the limited options available. Erythromycin ethylsuccinate is a potent prokinetic agent that stimulates gastric emptying. Recently, erythromycin has been linked to the occurrences of sudden cardiac death due to QT prolongation. Azithromycin is similar to erythromycin in structure but does not have significant drug-drug interactions as seen with erythromycin. Purpose: This study aims to determine whether azithromycin stimulates antral activity in patients with chronic gastrointestinal pain and refractory gastroparesis. Methods: Small bowel manometric data on 30 patients undergoing clinical evaluation for chronic digestive problems or documented refractory gastroparesis were reviewed. Antral activity was measured after infusion of erythromycin 250 mg intravenous and azithromycin (500 or 250 mg intravenous) given at different intervals during the small bowel manometry. The parameters measured included the total duration of effect, mean amplitude of antral contractions, duration of the highest antral contraction phase, number of cycles per minute, and the motility index. Results: Comparison of erythromycin and azithromycin at similar doses showed a similar positive effect on antral activity. However, comparison of erythromycin and azithromycin at the higher dose of 500 mg showed that the mean amplitude, duration of antral activity, and motility index were significantly increased with azithromycin (P < 0.05). Conclusions: Azithromycin stimulates antral activity similar to erythromycin and moreover has a longer duration of effect. However, unlike erythromycin, azithromycin does not have significant drug-drug interactions and may be a potential new medication for the treatment of gastroparesis and gastrointestinal dysmotility.

AB - Background: Current pharmacologic treatments for gastroparesis have been disappointing due to the limited options available. Erythromycin ethylsuccinate is a potent prokinetic agent that stimulates gastric emptying. Recently, erythromycin has been linked to the occurrences of sudden cardiac death due to QT prolongation. Azithromycin is similar to erythromycin in structure but does not have significant drug-drug interactions as seen with erythromycin. Purpose: This study aims to determine whether azithromycin stimulates antral activity in patients with chronic gastrointestinal pain and refractory gastroparesis. Methods: Small bowel manometric data on 30 patients undergoing clinical evaluation for chronic digestive problems or documented refractory gastroparesis were reviewed. Antral activity was measured after infusion of erythromycin 250 mg intravenous and azithromycin (500 or 250 mg intravenous) given at different intervals during the small bowel manometry. The parameters measured included the total duration of effect, mean amplitude of antral contractions, duration of the highest antral contraction phase, number of cycles per minute, and the motility index. Results: Comparison of erythromycin and azithromycin at similar doses showed a similar positive effect on antral activity. However, comparison of erythromycin and azithromycin at the higher dose of 500 mg showed that the mean amplitude, duration of antral activity, and motility index were significantly increased with azithromycin (P < 0.05). Conclusions: Azithromycin stimulates antral activity similar to erythromycin and moreover has a longer duration of effect. However, unlike erythromycin, azithromycin does not have significant drug-drug interactions and may be a potential new medication for the treatment of gastroparesis and gastrointestinal dysmotility.

KW - Antroduodenal manometry

KW - Azithromycin

KW - Erythromycin

KW - Functional gastrointestinal pain

KW - Gastrointestinal dysmotility

KW - Gastroparesis

UR - http://www.scopus.com/inward/record.url?scp=77949333280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949333280&partnerID=8YFLogxK

U2 - 10.1007/s10620-009-1038-3

DO - 10.1007/s10620-009-1038-3

M3 - Article

VL - 55

SP - 675

EP - 683

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -